DelRicht Research is proud to spotlight the exceptional performance of our investigators and site teams in a U.S.-based Phase 2/3 clinical trial evaluating treatment for androgenetic alopecia (AGA), a condition that affects millions of males and females and is characterized by progressive loss of terminal hair of the scalp. 

Over a ten-month enrollment period, our network dramatically outperformed enrollment expectations, securing a leadership role among participating sites nationwide.

Outpacing Enrollment Targets

The sponsor’s objective for this dermatology study was to recruit 498 participants across 44 sites in the United States. DelRicht set a goal of 70 participants across two sites. By the close of enrollment, our teams had exceeded this target more than threefold, enrolling 70 participants and reaching 310% of our expected goal.

This level of performance highlights the strength of DelRicht’s operational model, pairing efficient study execution with deep community engagement.

Addressing Study Challenges with Careful Communication

A unique element of this trial was the requirement for participants to have a small area of scalp clipped and marked with an ink dot tattoo. This process was essential for ensuring consistent photography and reliable evaluation of hair regrowth over time. While medically minimal, the procedure initially raised concerns for some patients, leading to hesitation during screening.

DelRicht proactively addressed this challenge through clear, patient-friendly education and transparent communication. Site coordinators were equipped with tailored materials to help explain each step of the process, reassure participants, and emphasize how the procedure ensured accurate, credible results. By normalizing the requirement and positioning it as a critical contribution to scientific progress, our teams helped participants feel comfortable, supported, and confident in moving forward.

The Study and Investigators

This pivotal Phase 2/3 trial focused on adult male participants ages 18–65 with mild to moderate androgenetic alopecia. DelRicht partnered with two highly regarded investigators, whose leadership was instrumental in driving outcomes:

Dr. Ira Thorla | LA Dermatology Associates | Baton Rouge, LA
Dr. Robert Springer | Springer Wellness & Restorative Health | Atlanta, GA

Their clinical expertise and trusted community relationships allowed for efficient recruitment, excellent patient retention, and high-quality data capture.

What This Means for Sponsors and CROs

The success of this trial underscores the value of partnering with a network that can deliver results in highly competitive therapeutic areas such as dermatology. Key takeaways include:

Exceptional Enrollment: Achieving 310% of assigned goal, placing DelRicht among the trial’s top contributors.
Patient-Centered Education: Addressing protocol-specific concerns through clear communication and supportive engagement.
Investigator Excellence: Leveraging respected community-based physicians to drive both enrollment and retention.
Operational Precision: Ensuring protocol adherence while maintaining a positive participant experience.

Partner With Us

At DelRicht Research, our mission is to move medicine forward by pairing operational excellence with strong physician leadership and trusted community relationships. This trial demonstrates how even in protocols with unique patient requirements, our teams consistently deliver outcomes that accelerate timelines and strengthen data integrity.

If you are seeking a research partner capable of exceeding expectations in dermatology and beyond, we invite you to learn more at www.DelRichtResearch.com or connect with us directly to explore collaboration opportunities.